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To elucidate molecular mechanisms responsible for the sexually
dimorphic phenotype of soluble epoxide hydrolase (sEH) expression,
we tested the hypothesis that female-specific down-regulation of
sEH expression is driven by estrogen-dependent methylation of the
Ephx2 gene. Mesenteric arteries isolated frommale, female, ovariec-
tomized female (OV), and OVwith estrogen replacement (OVE) mice,
as well as the human cell line (HEK293T) were used. Methylation-
specific PCR and bisulfite genomic sequencing analysis indicate sig-
nificant increases in DNA/CG methylation in vessels of female and
OVE compared with those of male and OV mice. The same increase
in CG methylation was also observed in male vessels incubated with
a physiological concentration of 17β-estradiol (17β-E2) for 48
hours. All vessels that displayed increases in CG methylation
were concomitantly associated with decreases in their Ephx2
mRNA and protein, suggesting a methylation-induced gene si-
lencing. Transient transfection assays indicate that the activity
of Ephx2 promoter-coding luciferase was significantly attenu-
ated in HEK293T cells treated with 17β-E2, which was prevented
by additional treatment with an estrogen receptor antagonist
(ICI). ChIP analysis indicates significantly reduced binding activi-
ties of transcription factors (including SP1, AP-1, and NF-κB with
their binding elements located in the Ephx2 promoter) in vessels
of female mice and human cells treated with 17β-E2, responses
that were prevented by ICI and Decitabine (DNA methyltransferase
inhibitor), respectively. In conclusion, estrogen/estrogen receptor-
dependent methylation of the promoter of Ephx2 gene silences sEH
expression, which is involved in specific transcription factor-directed
regulatory pathways.
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Sex hormones have the property to operate as transcriptionalregulators during the process of gene expression by serving as
ligands for nuclear hormone receptors, therefore yielding the
phenotype of sex-different gene expression. One potential gene
susceptible to the influence of sex hormones is the Ephx2 gene,
which encodes the soluble epoxide hydrolase (sEH) protein, an
enzyme responsible for converting cardioprotective epoxyeicosa-
trienoic acids (EETs), metabolites of arachidonic acids by cyto-
chrome P450 (CYP), to their corresponding non- or less-bioactive
dihydroxyeicosatrienoic acids. The identification of sexual di-
morphism of sEH activity, followed by cDNA cloning and ex-
pression of sEH from human and murine livers (1, 2), was originally
published around the 1980s, when sEH activity was demonstrated
to be remarkably higher in the liver and kidneys of male mice in
comparison with female littermates (3, 4), although little func-
tional relevance was reported in these pioneer studies. Only recently
has the sexually dimorphic regulation of sEH come to the forefront
of research, with aims to specifically evaluate the pathophysiological
significance of sEH, particularly in females. The rationale for the
present study was inspired by a phenomenon delineated as a
“male-specific hypotensive phenotype” that occurs in response to
the deletion of the Ephx2 gene (sEH-KO) or the use of sEH
inhibitors (sEHIs) and is characterized by significantly lower blood
pressure in male mice deficient in the Ephx2 gene/or sEH activity,
a response that failed to be initiated in their female counterparts
(5, 6). In this regard, we proposed that in vivo presence of female
hormones/estrogens heritably possesses an action that imitates the
effect caused by sEH-KO in males, which makes females insensitive
to additional disruption of the Ephx2 gene. This hypothesis was
verified by our, as well as by others’ studies, in both physiological
and pathological conditions. Indeed, findings of estrogen-dependent
suppression of sEH to increase tissue EETs in the cerebral circula-
tion provide mechanistically based evidence for a female-favorable
protection from cerebral ischemic damages (7, 8). We have also
provided evidence indicating that female-specific down-regulation
of sEH protein expression in cardiac, pulmonary, and vascular
tissues favors a greater contribution of EETs in females than males
and initiates the same cardiovascular responses as those observed
in male sEH-KO mice, or male mice treated with sEHIs (9–12).
Particularly in the microcirculation, a genetic deficiency in the
Ephx2 gene or down-regulation of sEH expression elicits signifi-
cantly enhanced flow/shear stress-induced vasodilation and atten-
uated pressure-induced vasoconstriction via an EET-dependent
mechanism in the mesenteric, coronary, and skeletal muscle arte-
rioles (9, 11, 13). To date, however, the responsible signaling and
specifics regarding which female hormones and receptors are in-
volved have been left unaddressed. To this end, we hypothesized that
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the sex-specific phenotype, in terms of female-led down-regulation of
sEH, is driven by estrogen-dependent methylation of the Ephx2 gene,
a response that is categorized as an epigenetic regulation.
Epigenetics is defined as “the interactions of genes with their
environment that bring the phenotype into being.” Epigenetics is
characterized as inheritable changes in the expression pattern
of a gene, which is not caused by alterations in the nucleotide
sequence of the genetic code per se, but rather triggered by
modifications in DNA-associated molecules, such as small non-
coding RNAs, or by chemical modifications of DNA, such as
DNA methylation (14). DNA methylation is a typical epigenetic
event that involves attachment of a methyl group (CH3) on the
5′ carbon position of the cytosine ring, and occurs basically at the
site of a CG dinucleotide (15), oligoes that are present mostly in
the promoter region of genes. Thus, the presence of putative
CpG sites and specific transcription factor (TF) binding elements
in the promoter region of the human Ephx2 gene (16, 17) provide
the molecular basis for the methylation-dependent silencing of
Ephx2 expression. The present study was therefore, conducted on
both freshly isolated mouse arteries and a human cell line to
verify the estrogen-induced down-regulation of Ephx2 gene ex-
pression as a result of CG methylation.
Results
Estrogen-Dependent Transcriptional Down-Regulation of sEH. To
verify that female-specific down-regulation of sEH expression
occurs at the transcriptional level, as a function of estrogen,
Ephx2 mRNA expression in mesenteric arteries isolated from
male and female mice, and male vessels incubated with a
physiological concentration of 17β-estradiol (17β-E2, 10 nM)
for 48 h, were assessed. Real-time RT-PCR analysis indicates
that female vessels exhibit a significantly reduced Ephx2 mRNA
level by ∼80% (Fig. 1A), concomitantly with the same reduction
in the protein expression (Fig. 1B) compared with male vessels.
Similarly, male vessels treated with 17β-E2 also displayed the
same suppression (∼80%) of Ephx2 mRNA (Fig. 1C) and pro-
tein content in a time-dependent manner (Fig. 1D), compared
with untreated controls, suggesting that the down-regulation of





Fig. 1. Changes in sEH mRNA (A and C) and protein expression (B and D) in
mesenteric arteries isolated from male and female mice (A and B) and male
arteries with and without treatment with 17β-estradiol (E2, 10 nM) for 48 h
(C). (D) Time-course of sEH protein expression in male vessels incubated
without (as control) and with E2 for 24, 48, and 72 h, respectively. *Signifi-
cant difference from controls (n = 5–6).
A
B
Fig. 2. (A) A mouse Ephx2 promoter region containing an ∼1,200-bp sequence upstream of the start codon (ATG in red), with 21 CpG sites numbered as −1 ∼ −21
(gray shadow). The primers for MSP are shownwith black underline arrows. The primers for both proximal (magenta underline arrows) and distal sequence (green
underline arrows), ChIP PCR primers (red underline arrows), and specific binding elements for transcription factors of SP1 (gray box), AP-1 (red box), and NF-κB
(blue box) are indicated. (B) Within the diagram of the mouse Ephx2 promoter region, each designated color or font pattern corresponds to the region on the
nucleotide sequence in A. Additionally, the position of each GpG site is demarcated by gray bars.
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The Promoter Region of the Ephx2 Gene. Fig. 2A presents the mouse
Ephx2 promoter region (GenBank accession no. AC126272.3). As
indicated, there is ∼1,200-bp sequence upstream of the Ephx2
coding region, containing 21 CpG sites, numbered from −1 to −21,
that is located upstream of the start codon (ATG in red). The
location of primers for both proximal (Fig. 2A, magenta underline
arrows) and distal sequencing (Fig. 2A, green underline arrows)
are marked. Specific binding elements for the TFs SP1 (Fig. 2A,
gray box), AP-1 (Fig. 2A, red box), and NF-κB (Fig. 2A, blue box)
are also indicated. In the present study, we focused on the meth-
ylation of CpG −13 and −15 using methylation specific PCR
(MSP) to determine the methylated/unmethylated ratio. The pri-
mers for MSP (Fig. 2A, black underline arrows) were picked up by
the software MethPrimer 2.0 (Li Laboratory, www.urogene.org/
methprimer/). Fig. 2B is a diagrammatic sketch of the promoter
region of Ephx2 gene.
Estrogen-Dependent Increase in Methylation of the Mouse Ephx2
Gene Promoter. The original tracing and summarized results
from MSP are depicted in Fig. 3. Fig. 3A demonstrates that DNA
methylation of CpG −13/−15 was significantly increased in vessels
of female compared with male mice, as indicated by a greater ratio
of methylated to unmethylated DNA (M/U) in female vessels,
thereby yielding a sex-different CG methylation. A similar increase
in methylation at CpG positions of −17/−18 of female vessels was
also observed (Fig. 3B). To clarify if estrogen or other female hor-
mones, such as progesterone, are responsible for the sex-bias in
methylation of the Ephx2 promoter, MSP was performed on mes-
enteric arteries that were isolated from ovariectomized (OV) female
mice, OV mice with replacement of estrogen (OVE), and male ar-
teries incubated with 17β-E2 (10 nM) or 17α-E2 (10 nM, physiolog-
ically inactive stereoisomer of E2) for 48 h. As shown in Fig. 3C,
vessels isolated from OV mice exhibited a significant decrease in the
methylation of CpG −13/−15 compared with vessels from intact fe-
males, which was comparable to vessels of male mice. Estrogen re-
placement (OVE) fully prevented the OV-induced reduction in
DNA methylation. The functional consequence of ovariectomy was
validated by the significant decreases in plasma 17β-E2 and uterus
weight in an estrogen replacement-reversible manner. Moreover,
treatment of male vessels with 17β-E2, but not 17α-E2, significantly
increased DNA methylation (Fig. 3 D and E). Collectively, results
from both in vivo (females and OVE) and in vitro (male vessels
treated with 17β-E2) treatment with estrogens provide solid evidence
indicating that the sex-different methylation of the mouse Ephx2






Fig. 3. Original tracing and summarized data from MSP showing the ratio of methylated (m) to unmethylated (u) CG −13/−15 (A and C–E) and CG −17/−18 (B) in
mesenteric arteries isolated frommale (M) and female (F) mice (A and B), female mice with OV, and OVE (C), and male vessels treated with and without 10 nM 17β-E2 (D
and E) or 17α-E2 (E). *Significant difference from male and OV. †Significant difference from male, female and OV (n = 4–6 for each group, except for E).







Predominant Methylation of the Female Ephx2 Promoter. Bisulfite
genomic sequencing (BGS) analysis was performed to investigate the
CpG methylation status in flanked sequences of the major MSP
amplicon and to provide a general profile of sex-differential meth-
ylation of the promoter. As shown in Fig. 2, there were 12 CpGs in
the approximate sequencing region. The majority of these CpGs were
unmethylated, but associated with more methylated mixture in fe-
males compared with males. On the other hand, Table 1 summarizes
the results from the distal sequencing region (CpG sites −16 to −19)
showing that both males and females exhibited decreases in meth-
ylation from upstream promoter toward the coding region (from
CG −19 to −16), but females presented a greater potential for
methylation of these CpG sites than males.
Specific Target Region for Estrogen-Mediated Methylation in the
Ephx2 Promoter. To identify the specific target region of the Ephx2
promoter responsible for the estrogen-dependent methylation, as
well as possible roles of estrogen receptors (ERs) in the mediation of
estrogen responses, a luciferase-based reporter assay was conducted
on a human cell line (293 cells). Fig. 4 shows that in comparison with
pGL3-CMV, transfection with the pGL3-sEH promoter (0.4-kb
fragment containing two groups of multiple SP1 binding sites, and
one AP-1 and one NF-κB binding site, respectively) elicited an ∼40%
of total activation induced by the positive control. This activation was
significantly attenuated by 17β-E2 (sEH promoter + 17β-E2), and
completely reversed by the addition of an ER blocker (sEH
promoter + 17β-E2 + ICI 182,780). These results indicate that
17β-E2 directly methylates the Ephx2 promoter region to inhibit
sEH transcription via an ER-dependent mechanism. Alternatively,
a shorter form of the Ephx2 promoter, which includes a deletion of
a 0.4-kb promoter with a 0.12-kb fraction (upstream from five-
flanking regions of putative transcriptional start codon of Ephx2)
and contains only one group of SP1 binding sites, was also used. In
response to transfection with the shorter promoter, treatment with
17β-E2 failed to significantly affect luciferase activity, negating the
importance of the proximate end of the human Ephx2 promoter as
a major target area for estrogen. Noteworthy, both human (Fig. 4)
and mouse Ephx2 promoters (Figs. 1–3) exist with an identical
responsiveness to 17β-E2, pointing to estrogen-dependent epige-
netic regulation of the Ephx2 gene as being universally applicable.
Estrogen/ER Attenuation of TF Binding Activity. TFs play crucial
roles in the regulation of gene expression, and both human and
mouse Ephx2 promoter regions contain SP1, AP-1, and NF-κB
binding elements (18) (Fig. 2). We therefore performed a ChIP
assay to test whether a sex-bias exists in TF binding activities, and
if so, whether the change in TF binding is attributed to the es-
trogen-dependent methylation of the Ephx2 promoter (Figs. 3 and
4). Fig. 5A shows the significant attenuation of SP1 and AP-1
binding activities in female vessels compared with those of males,
whereas the reduction in NF-κB binding activity of females was not
statistically significant (P = 0.065) from male littermates. A ChIP
assay was also performed in human cells, and similar results were
observed. As indicated, the treatment of 293T cells with a physi-
ological dose of 17β-E2 elicited significant decreases in SP1 (Fig.
5B), AP-1 (Fig. 5C), and NF-κB (Fig. 5D) binding activities, re-
vealing a functionally identical responsiveness with mouse vessels
(Fig. 5A). At CG-rich promoter elements, the reduced SP1 binding
activity was prevented by ER antagonist and a DNA methyl-
transferase (DNMT) inhibitor (5-Aza-CdR), respectively, implying
an estrogen/ER-dependent DNA methylation of the binding se-
quences. However, alternative pathways that are capable of being
activated by estrogen/ERs may be involved in the mediation of
reductions in AP-1 and NF-κB binding activities.
Taken together, our results illustrate an integrated network
that operates in concert with estrogen, ERs, DNA methylation,
and TF binding activities to process the modulation of Ephx2
gene expression.
Discussion
We provide direct evidence that the molecular nature of the
sexually dimorphic phenotype of sEH expression is an epigenetic-
based event, by which estrogen, through ERs, methylates the
Ephx2 gene promoter to silence the gene expression. In particular,
specific TF binding motifs act as targets for estrogen to initiate
DNA methylation (mainly in the CG-rich SP1 motif), or as a
consequence of methylation in compromising access of their li-
gands (such as binding of c-jun or c-Fos with the AP-1 motif).
While a previous study has reported methylation-induced Ephx2
gene silencing involved in SP1-binding activity in carcinoma
HEPG2 cells (17), our studies identify CGmethylation at the Ephx2
gene promoter as being triggered by estrogen. During this process,
specific TFs interface with both methylation-direct and -indirect
procedures to collectively constitute the main component of
estrogen-mediated signaling through combinatorial and co-
ordinated actions, leading to estrogen-specific physiological
down-regulation of Ephx2 gene/sEH expression. Our findings
uncover the molecular mechanism that provides explanations
for the sexual dimorphism of sEH expression (3, 19) and all of
the consequences arising there, defined as a female-favorable
protection against cardiac and cerebral ischemia (7–12).
To unravel the mystery of a sexual dimorphism of Ephx2 gene
expression, an epigenetic event emerged as our first consider-
ation, since the definition of epigenetics states that heritable
Table 1. Ratio of C/T (%) in CpG sites of upstream end of Ephx2
promoter
CG position −16, % −17, % −18, % −19, %
Male (n = 2) 32.5 35 52.5 67.5
Female (n = 2) 45 47.5 65 87.5
The percentage was calculated by estimating peak areas from each mouse
using a Finch TV image.
Fig. 4. Luciferase activity on human 293 cells transfected with different
plasmids of pRL or pGL3 under the control of different promoters, including
vector, CMV, and sEH promoters, respectively, in the absence and presence
of 17β-E2 (E2, 10 nM) or E2 pus ICI 182,780 (ICI, 100 nM). *Significant dif-
ference from transfection with sEH promoter (0.4 kb) alone, and from the
0.4-kb sEH promoter plus E2 and ICI, respectively (n = 3–6).
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changes in the gene phenotype depend on the surrounding en-
vironment (15). In this context, an inherent cellular atmosphere
that differs from one sex to the other can be primarily attributed
to sex hormones. Indeed, the differential expression of certain
genes that are selective targets of sex hormones, or are capable
of being regulated by sex hormones, have been believed to be
responsible for predisposing or protecting either of the sexes to
or from cardiovascular diseases. In general, roles of female
hormones/estrogens in the genetic regulation of target genes
have been extensively studied (20); however, little is known re-
garding the estrogen-dependent epigenetic regulation of genes,
in particular, via methylation-mediated signaling, which indeed,
plays a fundamental role in the regulation of physiological and
pathological processes. Given the presence of an unaddressed
research subject for the physiological significance of epigenetic
regulation of sEH by female hormones, we designed the studies
aimed to answer the questions as to whether the female-specific
phenotype of sEH expression is estrogen-dependent and is me-
diated by ERs. If so, whether the regulation is driven by DNA
methylation and what transcription factors are involved?
Estrogen/ER Mediates Methylation of the Ephx2 Promoter. Exposure
of male vessels to exogenous estrogen significantly decreased
Ephx2 mRNA (Fig. 1C) to the level induced by endogenous
estrogens in females (Fig. 1A), indicating that the nature of fe-
male-specific down-regulation of sEH is an estrogen-dependent
response. Consequentially, the suppression of Ephx2 mRNA is
concomitantly associated with the same reduction in sEH protein
levels (Fig. 1 B and D), as we reported previously (9–13, 20),
demonstrating that regulation of sEH by estrogen is at the tran-
scriptional level. We then indicated that DNA methylation is a
crucial step in the estrogen/ER-governed regulatory process for
Ephx2 expression. There is a similar outline of DNA methylation
pattern in Ephx2 promoter of both sexes and associated with a
remarkably increased density of unmethylated CpGs from 5′- to
3′- of the promoter. This conclusion was drawn based on our se-
quencing results: CpG −1 to −12 (3′-end of the promoter) were
basically unmethylated, and CpG −19 to −16 (5′-end of the pro-
moter) showed a transition from methylated to the unmethylated
(Table 1). On the other hand, although the Ephx2 gene consisted
of major unmethylated CpGs in the proximate promoter region, a
sex-bias, as indicated by a female-facilitated methylation presented
in the distal promoter region (Table 1), could be discerned. Fur-
thermore, the estrogen-dependent nature is verified by Fig. 3,
which shows that both in vivo (Fig. 3 A–C) and in vitro (Fig. 3 D
and E) presence of estrogen significantly enhanced vascular
methylation of the Ephx2 promoter at CG −13/−15 and CG −17/−18.
The increase in methylation of CpGs in the Ephx2 promoter is in-
versely proportional to its gene expression (Fig. 1A), supporting the
general concept of negative correlation between DNA/CG methyl-
ation and transcriptional activity. As such, our data strongly confirm
that the increase in CG methylation of the Ephx2 promoter, as a
function of in vivo (intact female and OVE vessels) and in vitro (17β-
E2–treated male vessels) stimulation with estrogen, is causative of
silencing the Ephx2 gene. This conclusion was further verified by the
result that blockage of ERs completely prevented the 17β-E2–induced
reduction in the activity of Ephx2 promoter-coding luciferase (Fig. 4).
Additionally, DNA binding motifs in the Ephx2 promoter that appear
to be most applicable to evoking estrogen/ER-dependent responses
were implicated, as indicated by the fact that in response to 17β-E2,
transfection of cells with a 0.4-kb promoter, but not a 0.12-kb frag-
ment, initiates a significant attenuation of luciferase activity (Fig. 4).
Thus, the DNA binding elements located in the Ephx2 promoter
region are important contributors to estrogen-evoked methylation-
mediated regulatory response.
In regards to whether estrogen regulates methylation specifi-
cally at a certain region of the genome (such as Ephx2 promoter)
or plays a broader role in DNA methylation, currently remains
unknown. In general, DNMTs determine the DNA methylation
pattern of the genome. Alterations in the expression or epige-
netic regulation of DNMTs will elicit methylation changes at
both regional and global genomic levels (21, 22). On the other
hand, besides the classic interaction of ligand-bound ER dimers
with estrogen-responsive elements in target gene promoters,
estrogen also regulates gene expression via multiple nonclassic
pathways. For example, the ER interacts with other DNA-bound
transcription factors (such as SP-1 and AP-1) via protein–protein
interactions, where it does not directly bind the promoter DNA
(23). Moreover, the promoter region of the mouse DNMT in-
deed contains putative AP-1 binding sites (24). To this end,
elucidation of the signaling that specifically links estrogen/ERs,
transcription factors, DNMTs, and the Ephx2 promoter should
be the topic of future studies.
Estrogen Methylation of Ephx2 Promoter in a TF Binding-Relevant
Manner. Methylated DNA can prevent some transcription fac-
tors from binding to their targets, or recruit other factors nec-
essary for modulating gene expression (14, 16, 17). Binding at the
SP1 site located upstream of the transcription start site is
deemed necessary for suppressing Ephx2 promoter expression
(25). Thus, the CG-rich SP1 binding element (Fig. 2) may serve
as an indicator of functional coupling between estrogen and
SP1 methylation by means of direct methylation with estrogen in
an ER-dependent manner. As we have found, an increase in
Ephx2 promoter methylation by estrogen (Fig. 3) is accompanied
with compromised SP1 binding activity in a Decitabine-reversible
manner (Fig. 5B), confirming the crucial role of SP1 binding in
the estrogen-dependent methylation of Ephx2 expression. Par-
ticularly, in terms of estrogen indirect actions, the estrogen/ER
complex can become tethered to DNA by interacting with TFs
(26–28) instead of directly binding to estrogen-responsive ele-
ments that are not found in the promoter of Ephx2 gene. We
believed that an interaction between SP1 and ERs, an event that
has been demonstrated to be necessary for estrogen-indirect
responses (27), contributes significantly to the methylation of
SP1 binding sites with estrogen.
Alternatively, a lesser presence of CpGs in the NF-κB and AP-1
binding areas have led to the speculation that binding reductions in
both of them can be, at least in part, mediated by alternative
events that are either methylation-independent, or more likely, an
indirect consequence of DNA methylation, which recruits or
prevents other actions necessary for silencing or enhancing Ephx2





Fig. 5. Ephx2 promoter binding activity of transcription factors including
SP1 (A and B), AP-1 (A and C), and NF-κB (A and D) in mouse arteries (A) and
human 293 cells (B–D) in control conditions and in the presence of E2, E2 pus
ICI, and E2 plus Decitabine (Decit), respectively. *Significant difference from
males (A); and from their controls and E2 with ICI, respectively (B–D) (n =
5–8 for each group).







family of eukaryotic transcription factors (such as Jun and Fos,
and so forth), which work as gene modulators. An up-regulation
of the Ephx2 gene was reported to be mediated by an angioten-
sin II-dependent stimulation of c-jun binding to putative AP-1
(18). Furthermore, the cross-talk between ERα and AP-1 was
demonstrated to be important in the etiology and progression of
certain cancers that are sensitive to ER blockers (29). Thus, it is
plausible to assume that estrogen/ER-dependent methylation of
the Ephx2 promoter, followed by preventative access of other AP-1
binding ligands, participates reciprocally in prohibiting the binding
activity. Moreover, accumulating evidence has confirmed interac-
tions between NF-κB and estrogen/ERs in affecting one another
(28), the reduction in NF-κB binding could be dependent of es-
trogen-induced (i) direct down-regulation of NF-κB gene and
(ii) methylation of NF-κB binding sites to compromise binding
affinities of NF-κB and other ligands.
In conclusion, the present study demonstrates an estrogen-
dependent epigenetic regulation of the Ephx2 gene via DNA
methylation-direct and -indirect pathways, both of which converge
to form a highly interconnected network that regulates the Ephx2
gene expression through multiple TF-dependent signaling. Our
findings are of importance because of the beneficial effects of
having increased levels of vascular EETs via silencing of the Ephx2
gene. More intriguingly, identification of estrogen-induced physi-
ological down-regulation of sEH expression highlights a clinical
potential for using sEH inhibitors that share the same target with
estrogen, as substitutes at least in part, for estrogen-replacement
therapy. This is based on the fact that there is a weak correlation
between estrogen-replacement therapy and improvement of car-
diovascular function and, therefore, the America Heart Associa-
tion has made recommendation of avoiding estrogen-replacement
therapy as a possible means of preventing cardiovascular disease
in postmenopausal women (30), who may exist with an up-regulation
of sEH as a consequence of estrogen deficiency.
Materials and Methods
Animals and Vessels. Mesenteric arteries isolated from 12- to 15-wk-old male,
female, OV female, and OVE (31) were used. All protocols were approved by
the Institutional Animal Care and Use Committee of New York Medical Col-
lege and conformed to the guidelines of the National Institutes of Health and
the American Physiological Society for the use and care of laboratory animals.
Vessel and Cell Cultures. Isolated mouse vessels and the human cell line
HEK293T were used and incubated with or without 17β-estradiol (17β-E2,
10 nM) for 48 h.
qRT-PCR. The primers were designed in-house and synthesized by Fisher
Scientific customer services (Table S1).
BGS and MSP. The primers for MSP and BGS amplification are shown in Table
S1. Bisulfite modification was performed as described previously (32). The
BGS assay involved two PCR amplificons in the Ephx2 promoter region: the
proximate one from −217 to +57 bp with 21 CpG sites and the distal one
from −970 to −427 bp with 4 CpG sites. MSP-detected methylation was ex-
pression as the ratio of methylated/unmethylated CpG sites (CpG/TpG × 100).
Luciferase Activity Assay. Luciferase assay was assessed on human cells (293T)
(16) with or without 17β-E2 treatment.
ChIP Assay. ChIP PCR primers were shown in Table S1. ChIP assay was per-
formed based on the protocol of cross-linking ChIP (Abcam). Mouse vessels
from male and female, as well as human cells (293T) with or without 17β-
E2 treatment were used as a chromatin source.
See SI Materials and Methods for more details.
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